NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for Caki-1 Cells, (Kidney Epithelial Cells, HTB-46)
Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Effective and robust intracellular delivery
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download Caki-1 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for Caki-1 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems Caki1 Transfection Protocol: [PDF]
Download MSDS: [PDF]
Caki-1 Cell Line:
According to the American Cancer Society, renal carcinoma is sporadic in young people, with an average patient age being approximately 65 years old. Although the death rates for kidney cancer have slightly decreased, the incidence is on the rise and represents a significant public health problem. Clear cell carcinoma accounts for 92% cases of renal cell carcinoma, which is the most common form of kidney cancer, as per the National Institutes of Health. The Caki-1 kidney clear cell carcinoma cell line exhibits epithelial cell morphology and has proven to be a dependable transfection host. This cell line was established from renal carcinoma cells of a 49-year-old Caucasian male patient with clear cell carcinoma. Caki-1 tumorigenic cells are commonly employed for studying the human proximal tubule epithelium. These cells contain many microvilli, but few filaments. Also, Caki-1 cells have many small mitochondria and a well-developed Golgi apparatus and endoplasmic reticulum (ER). Altogen Biosystems provides robust lipid-based transfection reagent kits for the Caki-1 renal carcinoma cell line that can be utilized in gene expression studies as well as in drug discovery and biomedical research.
Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into Caki-1 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).
Figure 2. Protein expression of Lamin A/C in Caki-1 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into Caki-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1723)
- 1.5 ml (Catalog #1724)
- 1.5 ml CRISPR (Catalog #2123)
- 8.0 ml (Catalog #1725)